H.I.G. Capital, a global alternative investment firm with more than $50 billion of equity capital under management, is pleased to announce that one of its affiliates has completed the recapitalization of Navitas Life Sciences.
Headquartered in Princeton, NJ, Navitas is a global technology-enabled clinical research organization (CRO) providing outsourced data science (including biostatistics, statistical programming and data management), regulatory and safety services (including software and monitoring) and other full-service CRO capabilities to blue-chip large and mid-sized pharmaceutical and government clients. The company’s functional service expertise optimizes the clinical trial process, drives cost efficiencies for its clients and ensures adherence to regulatory compliance requirements. The company’s global operations span the United States, India, Europe and South America.
“We are delighted to partner with H.I.G. in our mission to accelerate global access to outstanding drug development outcomes by harnessing the power of technology and domain knowledge,” Srinivasan HR, CEO at Navitas, said. “H.I.G., with its global network and diverse experience across healthcare and life sciences, is an ideal partner to support Navitas’ continued growth as a global next generation CRO. We are excited to leverage H.I.G.’s capital and resources to accelerate our own growth initiatives while continuing to deliver outstanding service to our clients.”
“Navitas’ capabilities go well beyond a traditional CRO as the Company leverages its expertise and technology for innovation and growth,” Camilo E. Horvilleur, managing director at H.I.G. Capital, said. “As technology becomes an integral part of drug development value chain, we expect Navitas to become an increasingly important strategic partner to life sciences companies.”
